Higher incidence of mild cognitive impairment in familial hypercholesterolemia

American Journal of Medicine

Volumn 123, Issue 3, 2010, Pages 267-274

  Zambón, Daniel ^c   Quintana, Melibea ^c   Mata, Pedro ^c   Alonso, Rodrigo ^c   Benavent, Jaume ^d   Cruz Sánchez, Felix ^e   Gich, Jordi ^c   Pocoví, Miguel ^b   Civeira, Fernando ^b   Capurro, Sebastian ^c   Bachman, David ^a   Sambamurti, Kumar ^a   Nicholas, Joyce ^a   Pappolla, Miguel A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Médico de Familia Del Consorci d'Atencio Primria de Salut de l'Eixample Casanova   (Spain)

^e UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

Author keywords

Alzheimer's disease; Hypercholesterolemia; Lipoprotein receptors; Mild cognitive impairment

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; RISK FACTOR; BLOOD; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; FOLLOW UP; HYPERLIPOPROTEINEMIA TYPE 2; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; RETROSPECTIVE STUDY; SPAIN;

CHOLESTEROL, LDL; COGNITION; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RECEPTORS, LIPOPROTEIN; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 77950486318     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.08.015     Document Type: Article

References (34)

1. Masters CL, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain. 2006;129:2823-2839. (Pubitemid 44684506)
2. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308. (Pubitemid 29120227)
3. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885-890. (Pubitemid 14104991)
4. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest. 2005;115:1121-1129. (Pubitemid 40629026)
5. Pappolla MA, Smith MA, Bryant-Thomas T, et al. Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis. Free Radic Biol Med. 2002;33:173-181. (Pubitemid 34775189)
6. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321-331.
7. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:890-899. (Pubitemid 33055603)
8. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:6460-6464. (Pubitemid 28249035)
9. Sparks DL, Martin TA, Gross DR, Hunsaker JC 3rd. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech. 2000;50:287-290. (Pubitemid 30651168)
10. Pappolla MA, Bryant-Thomas TK, Herbert D, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61:199-205. (Pubitemid 36875301)
11. Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer's disease-epidemiological evidence. Acta Neurol Scand Suppl. 2006; 185:50-57. (Pubitemid 44015225)
12. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol. 2000;20: 2255-2260.
13. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17:14-20. (Pubitemid 28153361)
14. Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277-281.
15. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149-155. (Pubitemid 34827510)
16. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70(19 Pt 2):1795-1802. Epub 2008 Jan 16. (Pubitemid 351653958)
17. Newschaffer CJ, Bush TL, Hale WE. Aging and total cholesterol levels: cohort, period, and survivorship effects. Am J Epidemiol. 1992; 136:23-34.
18. Zlokovic BV, Yamada S, Holtzman D, et al. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med. 2000;6: 718.
19. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004; 173:55-68. (Pubitemid 38224196)
20. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis. 2005;180:155-160.
21. Junyent M, Gilabert R, Zambon D, et al. The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. Arterioscler Thromb Vasc Biol. 2005;25:2203-2208. (Pubitemid 41416322)
22. Pocovi M, Civeira F, Alonso R, Mata P. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin Vasc Med. 2004;4:67-74. (Pubitemid 38393293)
23. Yamamoto T, Davis CG, Brown MS, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984;39:27-38. (Pubitemid 15218222)
24. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
26. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;337:1158-1159.
27. Otfried Spreen ES. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. New York: Oxford University Press; 1998.
28. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006;367:1262-1270.
29. Portet F, Ousset PJ, Visser PJ, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry. 2006;77:714-718. (Pubitemid 43837193)
30. Canevari L, Clark JB. Alzheimer's disease and cholesterol: the fat connection. Neurochem Res. 2007;32:739-750. (Pubitemid 46481303)
31. Solomon A, Kareholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007;68:751-756. (Pubitemid 46667900)
32. Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol. 2007;64:103-107. (Pubitemid 46072431)
33. Elias MF, Beiser A, Wolf PA, et al. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000;57:808-813. (Pubitemid 30397182)
34. Cao D, Fukuchi K, Wan H, et al. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging. 2006;27:1632-1643. (Pubitemid 44344838)